Navigation Links
MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion
Date:7/16/2008

MOUNTAIN VIEW, Calif., July 16 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced that the positive results from a Phase 2 study evaluating the safety, tolerability and pharmacokinetics of MAP0004 in adult asthmatics were published in the July issue of Current Medical Research and Opinion. MAP Pharmaceuticals is developing MAP0004, an orally inhaled and self-administered therapy, as a potential treatment for migraine.

The study results, which were first announced last year, demonstrated that treatment with MAP0004 resulted in rapid and efficient systemic absorption of the therapeutic compound, dihydroergotamine (DHE), in asthmatic subjects, and that absorption was comparable to that observed in a previous study of healthy volunteers.

"Asthma and migraine have a high incidence of co-morbidity, so it was important to evaluate MAP0004 in patients with compromised pulmonary function," said Thomas A. Armer, Ph.D., chief scientific officer of MAP Pharmaceuticals. "In the study, MAP0004 was well tolerated by asthmatics with no effect on pulmonary function and with no serious adverse events reported."

About the Phase 2 Study

The Phase 2 study was a randomized, double-blind, placebo-controlled, crossover study of MAP0004 in 19 adult asthmatics. Each patient received three doses, one every week in randomized order over a 15-day period, including two 1.0 mg doses of MAP0004 and one dose of placebo. The 1.0 mg dose is twice the dose being studied in MAP Pharmaceuticals' Phase 3 trial. Spirometry was performed and blood draws were obtained at screening and at multiple times during each visit.

The study indicated that MAP0004 was well tolerated by subjects with compromised lung function, and
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... May 20, 2013  TNI BioTech, Inc. (OTCQB: TNIB), ... and mobilization of the body,s immune system using patented immunotherapy, ... Markets, OTCQB marketplace under the ticker symbol "TNIB" commencing ... real-time Level II stock quotes for TNIB at ... , CEO of TNI BioTech, Inc. stated, "We are ...
(Date:5/20/2013)...  Medicare Part D seniors in plans with ... costs, convenient access to pharmacies and other benefits, ... Associates released today by the Pharmaceutical Care Management ... seniors (9.5 million) are currently enrolled in plans ... lower costs, pharmacy choices, and overall value of ...
(Date:5/20/2013)... 2013 With herbal medicines relied upon by ... U.S. Pharmacopeial Convention (USP) will provide freely available public ... ingredients used in these products. Today, USP proposes the ... Herbal Medicines Compendium ( HMC ) for ... hmc.usp.org . HMC will provide standards ...
Breaking Medicine Technology:TNI BioTech, Inc. Stock to Begin Trading on the OTCQB Marketplace 2TNI BioTech, Inc. Stock to Begin Trading on the OTCQB Marketplace 3Survey: 85% of Part D Seniors in Preferred Pharmacy Plans are Satisfied With Costs, Pharmacy Choices 2New Compendium Offers Freely Available Testing Standards to Help Ensure the Quality of Herbal Ingredients Used in Traditional Medicines 2New Compendium Offers Freely Available Testing Standards to Help Ensure the Quality of Herbal Ingredients Used in Traditional Medicines 3
... Data Showed Clinically Meaningful Benefits for Patients ... LONDON, May 29 ,GlaxoSmithKline (GSK) today announced ... the U.S. Food and Drug Administration and ... Rezonic(TM)/Zunrisa(TM) (casopitant), a novel,investigational NK-1 receptor antagonist. ...
... Phase III Studies With Ofatumumab, Zalutumumab and Zanolimumab, ... (OMX:,GEN) reports today that the last patient to ... in the pivotal Phase III clinical trial,of ofatumumab ... received the last scheduled treatment., In order ...
Cached Medicine Technology:GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant) 2GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant) 3GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant) 4GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant) 5GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant) 6GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant) 7GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant) 8Genmab Announces Updates on Phase III Cancer Studies 2Genmab Announces Updates on Phase III Cancer Studies 3
(Date:5/20/2013)... 2013 VHA Inc., the national ... automated, provider-led population health improvement, announced a new ... and successfully pursue population health management with ... to accelerate the transition to value-based models of ... improvement suite of services, the offering integrates VHA ...
(Date:5/20/2013)... Washington, D.C., May 20, 2013 CosmosID, a leading data ... as part of a collaboration results on analysis of ... speed, specificity, and accuracy. , The Food and Drug ... number of commercially available probiotics, four of which have ... The purpose of the tests was to compare the ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 Headquartered in ... Levy Phillips & Konigsberg LLP (“LPK”) has ... White Plains, New York. LPK will better serve people ... Hudson Valley, including Westchester, Putnam, Rockland, Orange, and Dutchess ... affected by asbestos-related diseases throughout New York, New Jersey, ...
(Date:5/20/2013)... Finnish subjects and was led by Professor Samuli ... 28 genetic markers improved detection of individuals with ... risk ≥20%) over traditional risk factors. , Identification ... for CHD, because the current guidelines recommend statin ... that genetic markers could be useful in CHD ...
(Date:5/20/2013)... Dallas, TX (PRWEB) May 20, 2013 ... largest portfolio of employee benefit, payroll products and services ... announced that both are selected as finalists for the ... the Fastest-Growing Company of the Year category, and CompuPay ... Year. Each finalist will ultimately be a Gold, Silver ...
Breaking Medicine News(10 mins):Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 2Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 3Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 4Health News:CosmosID unveils new tool for faster, specific and accurate testing of probiotics products 2Health News:Westchester Mesothelioma Lawyers Open Office in White Plains, New York 2Health News:Westchester Mesothelioma Lawyers Open Office in White Plains, New York 3Health News:BenefitMall And CompuPay, Inc., A BenefitMall Company, Named As Finalists In 2013 American Business Awards 2Health News:BenefitMall And CompuPay, Inc., A BenefitMall Company, Named As Finalists In 2013 American Business Awards 3
... , , ARLINGTON, ... Health and Human Services Office of Inspector General (OIG) ignored ... including complex rehab, to seniors and people with disabilities who ... the Medicare Program: Supplier Acquisition Costs and Services" and dated ...
... OKLAHOMA CITY, Sept. 3 Surgical Hospital of ... partnered with Surgical Care Affiliates (SCA), one of the country,s ... is a state of the art hospital providing surgical services ... pain management, podiatry and orthopedics. SCA and a number of ...
... done to protect young knees, ankles and shoulders, researcher says ... all high school sports injuries are bad enough to keep a ... the pack in severe injuries, a new U.S. study finds. , ... girls experienced a greater rate of severe injury than boys in ...
... worldunderstand and prepare for contagious outbreaks, the National Institutes ... adds new research expertise to increase its capacity to ... inform public health officials and policymakers. In ... and infected people around the world. In 2003, a ...
... delaying needed care ends up raising health-care costs, study ... -- Patients who don,t trust the health-care system are ... health and raising overall health care costs, a new ... majority of whom were black, about their attitudes toward ...
... , , , , ... entered into a definitive agreement under which Embla will acquire Covidien,s ... the Sandman(TM) brand name. Financial terms of the transaction were ... conditions. , , The combined entity will form ...
Cached Medicine News:Health News:Federal Study on Power Wheelchair Costs in Medicare Is Misleading and Ignores Costs of Required Services for Beneficiaries 2Health News:Federal Study on Power Wheelchair Costs in Medicare Is Misleading and Ignores Costs of Required Services for Beneficiaries 3Health News:Surgical Hospital of Oklahoma to Partner with Surgical Care Affiliates 2Health News:High School Sports Put Players at Risk for Severe Injuries 2Health News:New grants expand US infectious disease modeling effort 2Health News:New grants expand US infectious disease modeling effort 3Health News:Mistrust May Cause People to Put Off Treatment 2Health News:Embla(R) Systems Announces the Acquisition of the Sandman(R) Sleep Diagnostic Business from Covidien(R) - Creating the World's Largest Sleep Diagnostic Company 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: